In this study, BRAF copy number gain and high-level amplification were associated with unfavorable clinicopathologic characteristics, including higher NPI scores, larger tumor size, high-grade tumors, hormone receptor–negative status, and non-luminal subtypes, compared to patients with no CNAs. The gene discussed is NR4A1; the disease is neoplasm.